Skip to content

BioCrude Technologies USA, Inc.: 10-Q filed 2025-08-13

What BioCrude Technologies USA, Inc. reported in its quarterly report filed 2025-08-13 (fiscal Q2 2025): 28 published measures, 77 facts as tagged in accession 0001731122-25-001111.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-13
Fiscal period
fiscal Q2 2025
Accession
0001731122-25-001111 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioCrude Technologies USA, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3011,659USD
At 2024-12-3119,094USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-30421,498USD
At 2024-12-31322,129USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-30-406,220USD
At 2024-12-31-299,033USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-47,041USD91
2025-01-01 to 2025-03-31-58,646USD90
2024-04-01 to 2024-06-30-64,468USD91
2024-01-01 to 2024-03-31-123,536USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-57,839USD181
2024-01-01 to 2024-06-30-165,467USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-3058,031USD181
2024-01-01 to 2024-06-30166,963USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-1,239USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-9,585,174USD
At 2024-12-31-9,479,487USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3050,798,915shares91
2025-01-01 to 2025-06-3050,798,915shares181
2024-04-01 to 2024-06-3050,796,743shares91
2024-01-01 to 2024-06-3050,796,743shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3050,798,915shares91
2025-01-01 to 2025-06-3050,798,915shares181
2024-04-01 to 2024-06-3050,796,743shares91
2024-01-01 to 2024-06-3050,796,743shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300USD/shares181
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300USD/shares181
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-3011,463USD
At 2024-12-3113,890USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-41,480USD91
2025-01-01 to 2025-06-3099,223USD181
2024-04-01 to 2024-06-30-63,604USD91
2024-01-01 to 2024-06-30-186,206USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-30196USD
At 2024-12-315,204USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-04-01 to 2025-06-305,561USD91
2025-01-01 to 2025-06-306,464USD181
2024-04-01 to 2024-06-30864USD91
2024-01-01 to 2024-06-301,798USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-30421,498USD
At 2024-12-31322,129USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3050,854,726shares
At 2024-12-3150,854,726shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-30196USD
At 2024-12-314USD
At 2024-06-30257USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-309,100,972USD
At 2024-12-319,100,972USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-06-3027,127USD
At 2024-12-3128,627USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-06-3037,374USD
At 2024-12-3137,374USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-06-3025,911USD
At 2025-03-3124,698USD
At 2024-12-3123,484USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-105,687USD181
2024-01-01 to 2024-06-30-188,004USD182

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-47,223USD91
2025-01-01 to 2025-06-30106,804USD181
2024-04-01 to 2024-06-30-64,501USD91
2024-01-01 to 2024-06-30-188,009USD182

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-47,041USD91
2025-01-01 to 2025-06-30-105,687USD181
2024-04-01 to 2024-06-30-64,468USD91
2024-01-01 to 2024-06-30-188,004USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-3041,480USD91
2025-01-01 to 2025-06-3099,223USD181
2024-04-01 to 2024-06-3063,604USD91
2024-01-01 to 2024-06-30186,206USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-06-302,427USD181
2024-01-01 to 2024-06-302,233USD182

Inspect the source

Entity
BioCrude Technologies USA, Inc. / CIK 0001690384
Captured
2026-09-21T17:24:05.073Z
SEC response SHA-256
89c76d3d401fe6afb068748f997c9daeba79c1147b3d9c59f4ddc55dd1617a16

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001690384.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))